1. Home
  2. MAC vs AXSM Comparison

MAC vs AXSM Comparison

Compare MAC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Macerich Company (The)

MAC

Macerich Company (The)

SELL

Current Price

$24.06

Market Cap

7.0B

Sector

Real Estate

ML Signal

SELL

Logo Axsome Therapeutics Inc.

AXSM

Axsome Therapeutics Inc.

SELL

Current Price

$135.86

Market Cap

7.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MAC
AXSM
Founded
1964
2012
Country
United States
United States
Employees
2845
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
7.5B
IPO Year
1994
2015

Fundamental Metrics

Financial Performance
Metric
MAC
AXSM
Price
$24.06
$135.86
Analyst Decision
Buy
Strong Buy
Analyst Count
16
22
Target Price
$26.87
★ $264.62
AVG Volume (30 Days)
★ 2.7M
1.0M
Earning Date
11-04-2026
11-02-2026
Dividend Yield
★ 2.73%
N/A
EPS Growth
11.36
★ 38.56
EPS
★ N/A
N/A
Revenue
★ $1,013,983,000.00
N/A
Revenue This Year
N/A
$49.25
Revenue Next Year
$8.59
$52.08
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 10.43
N/A
52 Week Low
$16.03
$123.00
52 Week High
$26.68
$260.19

Technical Indicators

Market Signals
Indicator
MAC
AXSM
Relative Strength Index (RSI) 46.97 36.03
Support Level $23.16 $123.00
Resistance Level $25.96 $225.16
Average True Range (ATR) 0.59 7.85
MACD -0.09 1.71
Stochastic Oscillator 9.00 42.78

Price Performance

Historical Comparison
MAC
AXSM

About MAC Macerich Company (The)

Macerich invests in premium mall assets. The company owns 28 regional malls in its consolidated portfolio and nine regional malls in its unconsolidated portfolio along with a power center and six other real estate assets. The company's total portfolio has 39.9 million square feet of gross leasable area and averaged $199 in sales per square foot over the 12 months ended in June 2026.

About AXSM Axsome Therapeutics Inc.

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Share on Social Networks: